S
Sparrow Pharmaceuticals
Sparrow Pharmaceuticals, Inc.
About Sparrow Pharmaceuticals
Sparrow Pharma is a biotechnology startup that is developing innovative treatments for endocrine disorders caused by the overproduction of cortisol, a hormone that can lead to serious health issues. The company's primary focus is on the development of their proprietary HSD-1 inhibitor, SPI-62, which aims to reduce the level of active intracellular steroids, believed to be the main cause of toxicities related to steroid overproduction.
Sparrow Pharma's business model is centered around the research, development, and commercialization of their novel treatments. Their target market includes patients suffering from conditions such as Endogenous Cushing’s Syndrome and Autonomous Cortisol Secretion, both of which are characterized by excess cortisol production. Currently, these conditions are treated with therapies that have limited efficacy and serious side effects, or surgery, which carries its own risks. Sparrow Pharma's SPI-62 has the potential to offer a more effective and safer alternative.
The company generates revenue through the development and eventual sale of their pharmaceutical products. As a startup in the biotech industry, Sparrow Pharma is likely to also rely on funding from investors and grants for research and development.
In summary, Sparrow Pharma is a promising biotech startup that is leveraging insights into cellular biology to develop potentially revolutionary treatments for endocrine disorders.
Source: Dealroom company dataKnowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Sep 2025 | $95M | $380M | RA Capital Management · U.S. Venture Partners · RiverVest Venture Partners · OrbiMed | ↗ |
| EARLY VCOther financing | Apr 2024 | $10M | $250M | RiverVest Venture Partners · U.S. Venture Partners · OrbiMed | ↗ |
Growth signals
Latest recorded traffic for Sparrow Pharmaceuticals is 1.9K monthly website visits, down 9.5% over the last three months. Sparrow Pharmaceuticals's team grew 11.8% over the past year.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
OrbiMed
U.S. Venture Partners
RiverVest Venture Partners
RA Capital Management
Forbion Capital Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Sparrow Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Sparrow Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.